Latest Developments

MEKanistic Therapeutics Announces FDA Clearance of IND for MTX-531, Enabling Phase 1 Trial in Advanced Solid Tumors

First-patient dosing is anticipated in the third quarter of 2026 in a U.S. Phase 1 study of a first-in-class dual PI3K/EGFR inhibitor.

MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K Investigational Therapy, MTX-531, Demonstrates Significant Tolerability and Durable Tumor Regressions in Preclinical Cancer Models

New MTX-531 research in Nature Cancer highlights a promising dual-inhibitor strategy for overcoming cancer resistance.

MEKanistic Therapeutics First-in-Class Cancer Clinical Candidate Approved to Receive Continued Development Support through the NCI's Experimental Therapeutics (NExT) Program

MEKanistic's first-in-class highly targeted compound blocks EGFR and PI3K and demonstrated impressive tumor shrinkage and tolerability in preclinical studies.

Finding “The Goldilocks Zone” for Kinase Inhibitors

How to regulate kinase activity to arrest cancer while avoiding unmanageable toxicity in healthy cells.

MEKanistic Therapeutics announces the appointment of Dr. Patricia LoRusso to its Scientific Advisory Board

Dr. LoRusso brings more than 30 years of oncology and translational science experience to the scientific advisory board.

Invenshure Launches MEKanistic Therapeutics

Led by cancer research pioneers, MEKanistic introduces a breakthrough drug that more effectively shrinks tumors with less toxicity in preclinical trials.